Education
About Us
Working with TipRanks
Follow Us
Bristol-Myers Squibb (BMY)
NYSE:BMY
BMY Stock Chart & Stats
Day’s Range― - ―
52-Week Range$42.96 - $63.33
Previous CloseN/A
Volume3.98M
Average Volume (3M)13.09M
Market Cap
$90.03B
Enterprise Value$131.71B
Total Cash (Recent Filing)$11.78B
Total Debt (Recent Filing)$51.24B
Price to Earnings (P/E)17.8
Beta0.23
Next Earnings
Oct 30, 2025EPS Estimate
1.69Last Dividend Ex-Date
Jul 03, 2025Dividend Yield5.37%
Share Statistics
EPS (TTM)1.46
Shares Outstanding2,035,435,800
10 Day Avg. Volume14,540,022
30 Day Avg. Volume13,091,735
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)7.02
Price to Sales (P/S)2.37
P/FCF Ratio8.22
Enterprise Value/Market Cap1.46
Enterprise Value/Revenue2.76
Enterprise Value/Gross Profit4.67
Enterprise Value/Ebitda8.13
Forecast
1Y Price Target
$51.63Price Target Upside12.61% Upside
Rating ConsensusHold
Number of Analyst Covering20
Bulls Say, Bears Say
Bulls Say
Financial PerformanceBristol-Myers Squibb reported a meaningful beat on the topline and EPS, with both Growth and Legacy portfolios contributing to the beat.
Future OutlookGuidance for FY25 revenue was raised by $700 million, indicating strong future performance expectations.
Bears Say
Clinical TrialsThe timeline for Cobenfy’s Alzheimer’s Disease Psychosis trial could be impacted by internal reviews, with top-line data expected later than initially anticipated.
Earnings QualityConcerns remain around the quality of the earnings beat, particularly the reliance on lower quality items such as legacy products, FX, and stocking.
Revenue ProjectionsThe price target for Bristol-Myers Squibb was lowered from $55 to $53 due to reduced long-term projections for certain drugs.
Bristol-Myers Squibb News
BMY FAQ
What was Bristol-Myers Squibb’s price range in the past 12 months?
Bristol-Myers Squibb lowest stock price was $42.96 and its highest was $63.33 in the past 12 months.
What is Bristol-Myers Squibb’s market cap?
Bristol-Myers Squibb’s market cap is $90.03B.
When is Bristol-Myers Squibb’s upcoming earnings report date?
Bristol-Myers Squibb’s upcoming earnings report date is Oct 30, 2025 which is in 85 days.
How were Bristol-Myers Squibb’s earnings last quarter?
Bristol-Myers Squibb released its earnings results on Aug 01, 2025. The company reported $1.46 earnings per share for the quarter, beating the consensus estimate of $1.091 by $0.369.
Is Bristol-Myers Squibb overvalued?
According to Wall Street analysts Bristol-Myers Squibb’s price is currently Undervalued.
Does Bristol-Myers Squibb pay dividends?
Bristol-Myers Squibb pays a Quarterly dividend of $0.62 which represents an annual dividend yield of 5.37%. See more information on Bristol-Myers Squibb dividends here
What is Bristol-Myers Squibb’s EPS estimate?
Bristol-Myers Squibb’s EPS estimate is 1.69.
How many shares outstanding does Bristol-Myers Squibb have?
Bristol-Myers Squibb has 2,035,435,800 shares outstanding.
What happened to Bristol-Myers Squibb’s price movement after its last earnings report?
Bristol-Myers Squibb reported an EPS of $1.46 in its last earnings report, beating expectations of $1.091. Following the earnings report the stock price went up 2.124%.
Which hedge fund is a major shareholder of Bristol-Myers Squibb?
Currently, no hedge funds are holding shares in BMY
Bristol-Myers Squibb Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$51.63 (12.61% Upside)
$51.63 (12.61% Upside)
Blogger Sentiment
Bullish
BMY Sentiment 90%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 5.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 1.2%
Last 30 Days ▲ 0.6%
Last 30 Days ▲ 0.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-2.52%
12-Months-Change
Fundamentals
Return on Equity
29.31%
Trailing 12-Months
Asset Growth
0.03%
Trailing 12-Months
Company Description
Bristol-Myers Squibb
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
BMY Company Deck
BMY Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong performance in the growth portfolio and raised revenue guidance, demonstrating confidence in the company's strategic direction. However, unmet expectations in certain Phase III trials and the decline of the legacy portfolio were noted as challenges.View all BMY earnings summariesBMY Revenue Breakdown
70.61% U.S.
27.33% International
2.06% Other
BMY Stock 12 Month Forecast
Average Price Target
$51.63
▲(12.61% Upside)
Technical Analysis
Ownership Overview
0.05% Insiders
23.07% Mutual Funds
0.81% Other Institutional Investors
50.89% Public Companies and Individual Investors